Direxion Daily S&P Biotech Bull 3X ETF (LABU)
NYSEARCA: LABU · Real-Time Price · USD
295.76
-35.47 (-10.71%)
Aug 28, 2026, 4:00 PM EDT - Market closed
-10.71% (1D)
| Assets | $568.77M |
| Expense Ratio | 0.96% |
| PE Ratio | n/a |
| Shares Out | 1.97M |
| Dividend (ttm) | $1.01 |
| Dividend Yield | 0.34% |
| Ex-Dividend Date | Dec 23, 2025 |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| Volume | 530,470 |
| Open | 322.79 |
| Previous Close | 331.23 |
| Day's Range | 294.70 - 323.00 |
| 52-Week Low | 68.00 |
| 52-Week High | 341.93 |
| Beta | 2.41 |
| Holdings | 171 |
| Inception Date | May 28, 2015 |
About LABU
Fund Home PageThe Direxion Daily S&P Biotech Bull 3X ETF (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is issued by Direxion.
Asset Class Equity
Category Trading--Leveraged Equity
Region North America
Stock Exchange NYSEARCA
Ticker Symbol LABU
ETF Provider Direxion
Index Tracked S&P Biotechnology Select Industry
Top 10 Holdings
81.13% of assets| Name | Symbol | Weight |
|---|---|---|
| Goldman Finl Sq Trsry Inst 506 | n/a | 17.18% |
| S&P Biotechnology Select Industry Index Swap | n/a | 13.23% |
| S&P Biotechnology Select Industry Index Swap | n/a | 10.83% |
| Cash | n/a | 9.40% |
| S&P Biotechnology Select Industry Index Swap | n/a | 8.24% |
| Dreyfus Govt Cash Man Ins | n/a | 7.58% |
| S&P Biotechnology Select Industry Index Swap | n/a | 7.20% |
| S&P Biotechnology Select Industry Index Swap | n/a | 3.46% |
| Goldman Sachs Fin Gov 465 Institut | n/a | 2.12% |
| Moderna, Inc. | MRNA | 1.89% |
Dividend History
| Ex-Dividend | Amount | Pay Date |
|---|---|---|
| Dec 23, 2025 | $0.90971 | Dec 31, 2025 |
| Sep 23, 2025 | $0.10273 | Sep 30, 2025 |
| Jun 24, 2025 | $0.21897 | Jul 1, 2025 |
| Mar 25, 2025 | $0.10714 | Apr 1, 2025 |
| Jun 25, 2024 | $0.15021 | Jul 2, 2024 |
| Mar 19, 2024 | $0.16064 | Mar 26, 2024 |
Performance
LABU had a total return of 323.33% in the past year, including dividends. Since the fund's inception, the average annual return has been -18.94%.
News
Where to Buy Booming Biotech ETFs
Discover why biotech stocks are surging despite large fund outflows. Monitor these three industry ETFs for "buy the dip" opportunities.
7 years ago - Investopedia
Jablonski: Biotech presents a good buying opportunity
Sylvia Jablonski of Direxion discusses why biotech stocks and ETFs are attractive right now, due to their cheapness relative to the rest of the market.
7 years ago - CNBC Television